Exendins and exendin agonists for weight reduction and obesity

Details Exendins and exendin agonists for weight reduction and obesity Exendins and exendin agonists for weight reduction and obesity

2004-07-20

2010-06-22

Desai, Anand U (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S003100, 53, 53

Reexamination Certificate

active

07741269

ABSTRACT:
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5175145 (1992-12-01), Cooper
patent: 5187154 (1993-02-01), Phillips et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5574008 (1996-11-01), Johnson
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5686511 (1997-11-01), Bobo
patent: 6153432 (2000-11-01), Halvorsen et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6608038 (2003-08-01), Caplan et al.
patent: 6956026 (2005-10-01), Beeley et al.
patent: 7105490 (2006-09-01), Beeley et al.
patent: 7232798 (2007-06-01), Tran
patent: 199731732 (1997-06-01), None
patent: 0915910 (2006-01-01), None
patent: 0966297 (2008-12-01), None
patent: WO 9011296 (1990-04-01), None
patent: WO 9111457 (1991-08-01), None
patent: WO 9318786 (1993-09-01), None
patent: WO 9325579 (1993-12-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO 96/06626 (1996-03-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/19698 (1998-05-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 98/30231 (1998-07-01), None
patent: 99/07404 (1999-02-01), None
patent: WO 99/07404 (1999-02-01), None
DeFonseca et al. (2000) Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism. vol. 49, No. 6, pp. 709-717.
Al-Barazanji et al. (2000) Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. □□Obes Res. vol. 8, No. 4, pp. 317-323.
Wikipedia (2007, updated) Appetite, http://en.wikipedia.org/wiki/Appetite, pp. 1-2.
Anaspec (2007, updated) Exandin-4, http://www.anaspec.com/products/product.asp?id=32350, p. 1.
Obesity and diabetes (2007, updated) “Obesity and diabetes”, http://www.buzzle.com/editorials/ Oct. 6, 2005-78278.asp, pp. 1-3.
WikiAnswers (2008, updated) “What is the weight of an average lab mouse?”, http://wiki.answers.com/Q/ What—is—the—weight—of—an—average—lab—mouse, pp. 1-5.
Barinaga M. (1995) Obese″ protein slims mice, Science, vol. 269, No. 5223, pp. 475-476.
Wikipedia (downloaded from internet on Dec. 16, 2008) Routes of administration, http://en.wikipedia.org/wiki/Route—of—administration, pp. 1-3.
Collins et al. (1996) Pharmacologic Manipulation of ob Expression in a Dietary Model of Obesity, J. Biol. Chem., vol. 271, No. 16, pp. 9437-9440.
Yaswen et al. (1999) Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin, Nat. Med, vol. 5, No. 9, pp. 1066-1070.
Greeen et al. (1995)The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7, Genome Res., vol. 5, No. 1, pp. 5-12.
Cheah J. S. (2000) SMJ, Management of obesity in NIDDM, www.sma.org.sg/smj/3908 /articles/3908ra1.html, pp. 1-8.
Turton et al., Nature, vol. 379, pp. 69-72, 1996.
Goldstone et al, FEBS Letters, vol. 415, pp. 134=138, 1997.
Vandermeeers et al. European Journal of Biochemistry, 1987, vol. 164, pp. 321-327.
Strandberg et al (Acta Radiologlca, 1988, vol. 29, pp. 49-52).
GenBank Accession No. CAA24759, Feb. 9, 1999.
Navarro, M. et al., “Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake,”Journal of Neurochemistry, 67:1982-1991 (1996).
Bayer et al., “Advances in Poison Management,”Clin. Chem., 42(8)(B):1361-66 (1996).
D'Alessio et al., “Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal,”J. Clin. Invest., 93:2263-66 (1994).
Holst, “Glucagonlike Peptide-1: A Newly Discovered Gastrointestinal Hormone,”Gastroenterology, 107:1848-55 (1994).
Lawler et al., “Comparison of Effects of Amylin, Glucagon-like Peptide-1 (GLP-1) and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion in Rats,”Gastroenterology, 112(4):A194, (1997).
Miholic et al., “Glucagon-like Peptide-1 (GLP-1), Entleerung des Magenersatzes und das Dumpingsyndrom nach Gastrektomie,”Chirurgishes Forum, 1991, pp. 429-432 (English abstract and International Search Report in which the article is referenced are attached).
Nauck et al., “Effects of Subcutaneous Glucagon-like Peptide 1 (GLP-1 [7-36 Amide]) in Patients with Type 2-Diabetes,”Diabetologia, Abstract A148, 38 Supp. 1:A39 (1995).
Orskov et al., “Is the Effect of Glucagon-like Peptide-1 on Gastric Emptying Centrally Mediated?”,Diabetologia, Abstract A147, 38 Supp. 1:A39, (1995).
Ritzel et al., “GLP-1 [7-36 Amide] Augments Bisphasic Insulin Secretion After Intravenous Glucose in Healthy Volunteers,”Diabetologia, Abstract A145, 38 Supp. 1:A39, (1995).
Daniel et al. “Use of Glucagon in the Treatment of Acute Diverticulitis,”Br. Med. J., 3:720, 1974.
D'Alessio et al. “Elimination of the Action of glucagon-like Peptide 1 Causes an Impairment of glucose tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest., 97:133-38, 1996.
Eissele et al. “Rat Gastric somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,” Life Sci., 55:629-34, 1994.
Eng et al. “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,” J. Biol. Chem., 265:20259-62, 1990.
Eng et al. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom”, J. Biol. Chem., 267:7402-05, 1992.
Fehmann et al. “Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),” Peptides 15 (3): 453-6, 1994.
Ferguson et al. “Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures”, Annu. Rev. Biochem. 57:285-320, 1988.
Glauser et al. “Intravenous glucagon in the Management of Esophageal Food Obstruction”, J. Am. Coll. Emergency Physns, 8:228, 1979.
Gedulin et al. “Comparison of Effects of Amylin, Glucagon-like Peptide-1 and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion,”Diabetologia, 40 (Suppl. 1):A300 (Abstract 1181) (1997) 8:228, 1979.
Goke et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells”,J. Biol. Chem., 268:19650-55, 1993.
Kolligs et al. “Reduction of the Incretin effect in Rats by the Glucagon-Like Peptide 1 Receptor antagonist Exendin(9-39) Amide”, Diabetes, 44:16-19, 1995.
Malhotra et al. “Exendin-4, a new peptide fromHeloderma suspectumvenom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini”, Regulatory Peptides, 41:149-56, 1992.
Montrose-Rafizadeh et al. “Stru

Affiliated with

Also associated with

Rating

Exendins and exendin agonists for weight reduction and obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Exendins and exendin agonists for weight reduction and obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendins and exendin agonists for weight reduction and obesity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4158383